Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2020-06-10 Capital/Financing Update
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Licence Agreement with Jayex Healthcare 2 pages 224.9KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new software licence agreement between Lifespot Health and Jayex Healthcare. It details the terms of the licence, the products involved, and the strategic importance of the agreement. There is no financial data, no regulatory filing references, no meeting or voting information, no audit or management report content, and no mention of dividends or share transactions. The content is clearly an update on a business development or capital/financing activity related to licensing technology. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is about 5,369 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2020-06-10 English
Change in substantial holding 2 pages 138.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and shareholdings of substantial holders in Lifespot Health Ltd, including dates and nature of transactions. This type of filing is a notification of changes in major shareholdings, not a financial report or other corporate announcement. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2020-05-27 English
Notice of Annual General Meeting/Proxy Form 18 pages 515.0KB
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) for Lifespot Health Limited, detailing the meeting date, agenda, voting procedures, and resolutions to be considered. It includes information about the financial statements and reports for the year ended 31 December 2019, the adoption of the Remuneration Report, re-election of a director, and share issuance approvals. The document is a formal notice inviting shareholders to attend and vote at the AGM, not the actual Annual Report or financial statements themselves. It is lengthy (15,000 characters) and contains detailed meeting and proxy information, typical of an AGM Notice. Therefore, the correct classification is AGM Information (AGM-R).
2020-05-26 English
Change of Registered Office 1 page 112.1KB
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 22 May 2020 from Lifespot Health Limited regarding a change of the company's registered office address. It is an ASX announcement and does not contain financial data, management discussion, or any report content. It is a regulatory update about company contact details and office location, which fits best under Regulatory Filings (RNS) as it does not match any other specific category such as board changes, financial reports, or capital changes.
2020-05-21 English
Final Director's Interest Notice 2 pages 172.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including holdings and cessation of directorship. The content focuses on disclosure of personal shareholdings and interests of a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions or holdings by company directors and executives. The document length is short and specific to director interests, not a broader financial or management report.
2020-05-20 English
Initial Director's Interest Notice 2 pages 174.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the initial director's relevant interests in securities and contracts, with no securities held. This is a report of personal share transactions or interests by a company director. The document length is short and focused solely on director's interests, matching the definition of Director's Dealing filings. Therefore, the appropriate classification is DIRS (Director's Dealing).
2020-05-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.